Literature DB >> 15619670

Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state.

Nancy E Lane1, Wei Yao, Mary C Nakamura, Mary Beth Humphrey, Donald Kimmel, Xiaozhu Huang, Dean Sheppard, F Patrick Ross, Steven L Teitelbaum.   

Abstract

UNLABELLED: Integrin alphavbeta5 is expressed on osteoclast precursors and is capable of recognizing the same amino acid motif as alphavbeta3. Three-month-old beta5(-/-) female OVX mice had increased osteoclastogenesis ex vivo, and microCT assessment of trabecular bone volume was 53% lower than WT-OVX animals. These preliminary data suggest alphavbeta5 integrin's presence on osteoclast precursors may inhibit of osteoclast formation.
INTRODUCTION: Osteoclasts are unique resorptive skeletal cells, capable of degrading bone on contact to the juxtaposed matrix. Integrin alphavbeta5 is expressed on osteoclast precursors, structurally similar to alphavbeta3, and capable of recognizing the same amino acid motif. Given the structural relationship and reciprocal regulation of alphavbeta3 and alphavbeta5, the purpose of this study was to evaluate how alphavbeta5 might contribute to osteoclast maturation and activity.
MATERIALS AND METHODS: Three-month-old wildtype (WT) and beta5(-/-) female mice had ovariectomy (OVX) or sham operations. The osteoclastogenic capacity of marrow-derived precursors, the kinetic, the circulating, and structural parameters of bone remodeling, was determined after 6 weeks of paired feeding. RESULTS AND
CONCLUSIONS: OVX increased osteoclastogenesis ex vivo and in vivo. Osteoclast formation and prolonged pre-osteoclast survival were substantially enhanced in cultures containing beta5(-/-) cells whether obtained from sham-operated or OVX mice. Expression of cathepsin K, beta3 integrin subunit, and calcitonin receptor were accelerated in cultured beta5(-/-)osteoclasts. beta5(-/-) osteoclasts from OVX animals showed a 3-fold enhancement of net resorptive activity, with quantitative muCT showing trabecular bone volume loss after OVX 53% greater in beta5(-/-) OVX compared with similarly treated WT OVX mice (p < 0.05). alpha5beta3 seems to be an inhibitor of osteoclast formation, in contrast to alphavbeta3. In addition, loss of alphavbeta5 seems to accelerate osteoclast formation in the OVX model. Further examination of alphavbeta5 signaling pathways may enhance our understanding of the activation of bone resorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619670     DOI: 10.1359/JBMR.041017

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  26 in total

1.  HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.

Authors:  Ling Gao; Hongju Deng; Haibo Zhao; Angela Hirbe; John Harding; Lee Ratner; Katherine Weilbaecher
Journal:  Blood       Date:  2005-08-23       Impact factor: 22.113

2.  Osteoclasts: what do they do and how do they do it?

Authors:  Steven L Teitelbaum
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Targeting integrins to promote bone formation and repair.

Authors:  Pierre J Marie
Journal:  Nat Rev Endocrinol       Date:  2013-01-29       Impact factor: 43.330

4.  Modulation of acute lung injury by integrins.

Authors:  Dean Sheppard
Journal:  Proc Am Thorac Soc       Date:  2012-07

5.  Glucocorticoid dose determines osteocyte cell fate.

Authors:  Junjing Jia; Wei Yao; Min Guan; Weiwei Dai; Mohammad Shahnazari; Rekha Kar; Lynda Bonewald; Jean X Jiang; Nancy E Lane
Journal:  FASEB J       Date:  2011-06-24       Impact factor: 5.191

6.  Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

Authors:  W Yao; W Dai; L Jiang; E Y-A Lay; Z Zhong; R O Ritchie; X Li; H Ke; N E Lane
Journal:  Osteoporos Int       Date:  2015-09-18       Impact factor: 4.507

7.  Haploinsufficiency of Runx2 results in bone formation decrease and different BSP expression pattern changes in two transgenic mouse models.

Authors:  Qisheng Tu; Jin Zhang; Jeff Paz; Katherine Wade; Pishan Yang; Jake Chen
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

8.  Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.

Authors:  Wei Yao; Weiwei Dai; Mohammad Shahnazari; Aaron Pham; Zhiqiang Chen; Haiyan Chen; Min Guan; Nancy E Lane
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

9.  CD47 regulates bone mass and tumor metastasis to bone.

Authors:  Ozge Uluçkan; Stephanie N Becker; Hongju Deng; Wei Zou; Julie L Prior; David Piwnica-Worms; William A Frazier; Katherine N Weilbaecher
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

10.  Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice.

Authors:  Nancy E Lane; Wei Yao; Mehdi Balooch; Ravi K Nalla; Guive Balooch; Stefan Habelitz; John H Kinney; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2005-11-14       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.